Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01536886 · ClinicalTrials.gov registry record · Phase 2
LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris
A Phase 2 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 376
- Enrollment target
NCT01536886 is a Phase 2 study that has completed, run by LEO Pharma. The registered enrollment target is 376 participants.
The verdict
NCT01536886, a Phase 2 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 376 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate whether LEO 90100 and calcipotriol plus betamethasone are effective in the treatment of psoriasis vulgaris.
Interventions
- DRUG LEO 90100
- DRUG Betamethasone plus calcipotriol
- DRUG Ointment vehicle
- DRUG LEO 90100 vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2012-05 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01536886
The ClinicalTrials.gov registry entry for NCT01536886 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 376 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which LEO 90100 is the first listed.
NCT01536886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01536886 about?
NCT01536886 is a clinical study titled "LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris". The purpose of this study is to investigate whether LEO 90100 and calcipotriol plus betamethasone are effective in the treatment of psoriasis vulgaris.
What is the current status of trial NCT01536886?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 376 participants. The study started on 2012-05. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01536886?
The interventions under investigation include: LEO 90100 (DRUG), Betamethasone plus calcipotriol (DRUG), Ointment vehicle (DRUG), LEO 90100 vehicle (DRUG).
Who is sponsoring clinical trial NCT01536886?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.